CurifyLabs is proud to announce the launch of RoboPharma, a groundbreaking €5.6 million EU-funded initiative aiming to creating an AI and robotic driven, decentralised pharmaceutical EU manufacturing platform to enhance crisis preparedness across Europe by enabling high-precision production of essential medicines at the point of care.

The project is funded through the EU4Health programme, with a €3.4 million contribution from the European Union, and addresses one of the most pressing challenges in European healthcare: the fragility and inflexibility of centralized pharmaceutical supply chains during crises such as pandemics, natural disasters, and global disruptions.

RoboPharma’s mission is to develop and deploy a scalable, compliant, and intelligent pharmaceutical production platform specifically designed for hospital and community pharmacies. The system enables local production of personalized and high-demand medicines with unmatched speed, safety, and precision by leveraging robotic dosing technologies, AI-powered workflow automation, advanced connectivity, and real-time quality control.

“RoboPharma is not just a technological leap; it’s a strategic investment in Europe’s healthcare resilience. By empowering local pharmacies and hospitals with advanced production capabilities, we reduce bottlenecks, increase preparedness, and ensure uninterrupted access to critical medicines in shortage and crisis situations.” says Charlotta Topelius, CEO of CurifyLabs.

The RoboPharma consortium is led by CurifyLabs (Finland) and includes six forward-thinking partners across Europe:

• Delpech Pharmacy – France
• AtrimusRx – Sweden
• Vaasa Hietalahti Pharmacy – Finland
• Tartu University Hospital – Estonia
• Fysioline – Finland
• University Medical Center Mainz – Germany

Together, the partners will build, test, and validate the platform in real-world pharmacy and hospital settings, demonstrating its value in everyday operations and crisis scenarios alike.

By bringing production closer to the patient, RoboPharma improves crisis preparedness, brings solutions to address supply during drug shortages, and enhances the flexibility of pharmaceutical production in the EU. The result: readiness to utilize a more resilient, decentralized, and patient-centric pharmaceutical production approach for Europe.

Read more on the European Union website →

Stay tuned to follow the advancement of the project!

Co-funded by the European Union. Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union or HaDEA: Neither the European Union nor the granting authority can be held responsible for them.